Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
To demonstrate that import Mesalazine (Asacol®) is non-inferior to the reference drug,
marketed Mesalazine, regarding the primary endpoint (reduction of UC-DAI score)in patients
with active ulcerative colitis (UC) treated for 8 weeks.